1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Analysis of Agenus Inc

Analysis of Agenus Inc

  • March 2015
  • -
  • Aruvian's R'search
  • -
  • 105 pages

Agenus Inc. is a pharmaceutical manufacturing company that is involved in the development of a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines and adjuvants for the treatment of various cancers and infectious diseases. The company has in place a strong research and development team along with a strong portfolio of intellectual properties.

Aruvian’s R’search presents Analysis of Agenus Inc. A complete and comprehensive analysis of Agenus Inc., includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry, and then moves on to analyzing the company itself.

Company analysis from Aruvians includes a history of Agenus Inc., a business segment analysis of the segments Agenus Inc. operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the company’s major competitors.

A financial analysis of Agenus Inc. is presented in the report which includes a ratio analysis, basic profit and loss analysis, presentation of the company balance sheet, and much more.

A SWOT Framework Analysis of Agenus Inc. completes this in-depth company analysis.

Table Of Contents

Analysis of Agenus Inc
A. Executive Summary

B. Looking at the Industry
B.1 Industry Definition
B.2 Brief Profile of the Industry
B.3 Impacts on the Industry
B.4 Challenges Facing the Industry
B.5 Future Perspective

C. Industry PEST Framework Analysis
C.1 Political Aspects
C.2 Economic Aspects
C.3 Social Aspects
C.4 Technological Aspects

D. Looking at Agenus Inc.
D.1 Company Profile
D.2 History of the Company
D.3 Ownership Pattern in the Company
D.3.1 Major Holders
D.3.2 Major Direct Holders
D.3.3 Top Institutional Holders
D.3.4 Top Mutual Fund Holders
D.4 Organizational Divisions
D.5 Profiling the Key Executives
D.6 Products and Services

E. Looking at Business
E.1 Business Segments
E.2 Geographical Segments
E.3 Company Subsidiaries

F. SWOT Framework Analysis
F.1 Strengths to Build Upon
F.2 Weaknesses to Overcome
F.3 Opportunities to Exploit
F.4 Threats to Overcome

G. Profiling the Competition
G.1 Celldex Therapeutics, Inc.
G.1.1 Corporate Profile
G.1.2 Business Segments Analysis
G.1.3 Financial Analysis
G.1.4 SWOT Analysis
G.2 Idera Pharmaceuticals Inc.
G.2.1 Corporate Profile
G.2.2 Business Segment Analysis
G.2.3 Financial Analysis
G.2.4 SWOT Analysis
G.3 Northwest Biotherapeutics, Inc.
G.3.1 Corporate Profile
G.3.2 Business Segment Analysis
G.3.3 Financial Analysis
G.3.4 SWOT Analysis

H. Financial Analysis of Agenus Inc.
H.1 Current Financials
H.2 Balance Sheet
H.3 Profit and Loss Statement
H.4 Ratio Analysis
H.4.1 Capital Market Ratios
H.4.2 Annual Ratios
H.4.3 Quarterly Ratios

I. Future Perspective

J. Glossary of Terms

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 10 125
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6 995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Ovarian Cancer: Analytical Tool

August 2016 $ 7 125

Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • October 2016
  • Cancer  


    Brain Cancer  

  • United States  

    North America  

View report >

Cancer Statistics in Canada

  • October 2016
    11 pages
  • Cancer  

  • Canada  

    North America  

View report >

Pap Smear Industry in South Africa

  • October 2016
    14 pages
  • Pap Smear  

    Cervical Cancer  

  • South Africa  

View report >

Related Market Segments :



Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.